Business Context and Reporting Period
Capstone Therapeutics Corp. filed this unaudited Form 10-Q for the three months ended March 31, 2015. The filing identifies the registrant as Capstone Therapeutics Corp.; the provided metadata refers to Capstone Holding Corp. The company is a biotechnology business operating under a virtual model. It has no revenue-producing operations following the 2003 sale of its Bone Device Business and focuses primarily on the LipimetiX Development, LLC joint venture, which is developing AEM-28 and related Apo E mimetic peptides.
The joint venture completed its Phase 1a and Phase 1b/2a AEM-28 trials in 2014. Management reported a generally acceptable safety profile and statistically significant pharmacodynamic results for multiple lipid biomarkers in pooled data, but additional material development is currently constrained by funding.
Financial Performance and Position
| Metric | Three Months Ended March 31, 2015 | Three Months Ended March 31, 2014 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| General and administrative expense | $472,000 | $452,000 |
| Research and development expense | $350,000 | $630,000 |
| Total operating expenses | $822,000 | $1.082 million |
| Interest and other expense (income), net | $56,000 expense | $60,000 income |
| Income tax benefit | $162,000 | None reported |
| Net loss attributable to shareholders | $716,000 | $1.022 million |
| Basic and diluted loss per share | $0.02 | $0.02 |
| Cash flow used in operations | $624,000 | $768,000 |
At March 31, 2015, cash and cash equivalents were $1.540 million, down from $2.164 million at December 31, 2014 and $5.490 million at March 31, 2014. Total assets were $2.798 million and current liabilities were $365,000. The company reported total equity of $2.433 million and no debt other than the $700,000 revolving advance to the joint venture, which was due June 30, 2015.
Other current assets included an accrued Australian refundable research and development tax credit of AUD$447,000, reported as approximately $340,000 in U.S. dollars. The company had 40,885,411 common shares outstanding as of March 31, 2015 and April 30, 2015.
Operating cash use improved by $144,000 year over year, while the company made no investing or financing expenditures during either comparable quarter. The filing does not provide a meaningful operating margin because the company reported no revenue.
Material Changes Versus the Prior Comparable Period
- Net loss declined by approximately $306,000, or 30%, from $1.022 million to $716,000.
- Research and development expense declined by $280,000, primarily because the company significantly reduced AEM-28 development activities and the joint venture’s included expenses fell from $418,000 to $197,000.
- General and administrative expense increased by $20,000, primarily due to qui tam litigation and investor relations costs.
- Interest and other results changed from $60,000 of income to $56,000 of expense, primarily because the prior-year period included a $60,000 insurance-related receipt and the current period included a $57,000 foreign exchange loss related to Australian activities.
- The company recognized a $162,000 income tax benefit related to the Australian research and development credit.
- Cash declined by $624,000 during the quarter and was approximately 72% below the March 31, 2014 balance.
Outlook, Risks, Contingencies, and Unusual Items
Management stated that additional capital is required to continue operations and to resume or extend development of AEM-28 and its analogs. Planned 2015 activities are limited to monitoring and participating in the joint venture and maintaining corporate governance and SEC reporting, subject to available funding. Potential funding sources include strategic or merger transactions, debt or equity offerings, joint development arrangements, sales of development rights, and licensing transactions.
The financial statements were prepared on a going-concern basis, but management stated that substantial doubt exists regarding the company’s ability to continue as a going concern without additional funding. The company’s independent accounting firm had previously expressed substantial doubt in its report on the 2014 financial statements. Management warned that lack of funding within the next 12 months could impair current operations and continuation as a going concern.
The company’s principal legal contingency was a qui tam action related to its former bone growth stimulation business. In May 2015, the company agreed to a proposed one-time settlement of $50,000 and accrued that amount as of March 31, 2015. Court approval and dismissal were still pending when the filing was submitted. Management believed the expected settlement would not materially affect financial condition, liquidity, or results, but warned that an adverse litigation outcome could materially impair the business and its ability to continue operations.
The joint venture had $700,000 of outstanding revolving advances at March 31, 2015. If the joint venture cannot obtain funding and fails as a going concern, the company could incur an additional loss of $667,000 related to losses allocated to noncontrolling interests, in addition to potential losses associated with its net joint venture investment and advances. The filing states that the company could incur losses of up to, and possibly exceeding, $932,000 in connection with its net joint venture investment and revolving loan balance.
Material risks include unfavorable clinical or preclinical results, regulatory delays or non-approval, competition, intellectual property impairment, inability to secure partners or financing, and the impact of the qui tam matter on liquidity and strategic transactions. Management reported no material changes to the risk factors in the 2014 Form 10-K.
Investor Verification Points
- Verify the registrant’s legal name, because the filing identifies Capstone Therapeutics Corp., while the request metadata identifies Capstone Holding Corp.
- Confirm whether the proposed $50,000 qui tam settlement received court approval and whether the case was dismissed after the May 2015 filing date.
- Assess the company’s ability to raise capital and its liquidity runway given $1.540 million of cash, quarterly operating cash use of $624,000, and the stated going-concern uncertainty.
- Confirm the status and repayment or renewal terms of the $700,000 revolving advance to LipimetiX due June 30, 2015.
- Evaluate whether the Australian refundable research and development credit of approximately $340,000 was approved and collected.
- Monitor funding, partnering, regulatory, and clinical developments for AEM-28 and AEM-28-02, as no additional material development activities were funded at the reporting date.